Overview
A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.
Background
A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.
Indication
For the treatment of lead poisoning in pediatric patients with blood lead levels above 45 µg/dL. May also be used to treat mercury or arsenic poisoning.
Associated Conditions
- Arsenic Poisoning
- Lead Poisoning
- Mercury Poisoning
- Blood lead levels above 45 mcg/dL Lead poisoning
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/02/06 | Phase 2 | Recruiting | |||
2019/05/21 | Early Phase 1 | Recruiting | Second Affiliated Hospital, School of Medicine, Zhejiang University | ||
2018/08/15 | Phase 1 | Recruiting | |||
2013/12/23 | Phase 1 | Completed | U.S. Army Medical Research and Development Command | ||
2009/06/18 | Phase 1 | Completed | |||
2008/12/18 | Phase 1 | Completed | Southwest College of Naturopathic Medicine | ||
2006/09/14 | Phase 2 | Withdrawn | |||
2006/06/21 | Phase 3 | Completed | National Institute of Environmental Health Sciences (NIEHS) | ||
2000/02/25 | Not Applicable | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | 55292-201 | ORAL | 100 mg in 1 1 | 1/11/2023 | |
Theragnostics Inc | 71083-0020 | INTRAVENOUS | 1 mg in 1 1 | 1/31/2024 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Dimercaptosuccinic Acid Capsules | 国药准字H20074087 | 化学药品 | 胶囊剂 | 4/24/2022 | |
Dimercaptosuccinic Acid Capsules | 国药准字H20083389 | 化学药品 | 胶囊剂 | 4/24/2022 | |
Dimercaptosuccinic Acid Capsules | 国药准字H20051784 | 化学药品 | 胶囊剂 | 8/19/2024 | |
Dimercaptosuccinic Acid Capsules | 国药准字H10940167 | 化学药品 | 胶囊剂 | 8/19/2024 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
RADPHARM DMSA powder for injection | 14326 | Global Medical Solutions Australia Pty Limited T/A Radpharm Scientific | Medicine | A | 9/5/1991 |